【复方药影响趋缓+口服药在即 诺和诺德(NVO.US)市值腰斩后迎来价值重估】智通财经APP获悉,诺和诺德(NVO.US

智通财经
07 Jul
【复方药影响趋缓+口服药在即 诺和诺德(NVO.US)市值腰斩后迎来价值重估】智通财经APP获悉,诺和诺德(NVO.US)作为欧洲制药巨头,当前市值约3100亿美元,业务聚焦糖尿病与肥胖症护理、罕见疾病两大领域,TTM综合营业额达440亿美元。近期其股价经历剧烈回调,较历史高位缩水超52%,这一跌幅堪称公司历史上最陡峭的调整之一。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10